AtriCure Executive and Leadership Team

Michael Carrel, the President & Chief Executive Officer at AtriCure, directs the overarching strategic vision for the treatment of Atrial Fibrillation. Overseeing global market expansion, the President & Chief Executive Officer aligns research initiatives with long-term commercial objectives. This leadership role involves constant collaboration with the Board to ensure sustainable growth across North American and international medical markets. By prioritizing clinical innovation, Michael Carrel drives the development of advanced surgical technologies that address complex cardiac conditions. The President & Chief Executive Officer maintains rigorous standards for operational excellence while fostering a culture of medical advancement. Through consistent focus on patient-centric solutions, Carrel secures the competitive position of the company within the global healthcare landscape. This executive leadership ensures that all corporate activities remain tethered to the core mission of providing effective, life-changing therapies for patients suffering from cardiac arrhythmias.

Angela Wirick, the Chief Financial Officer at AtriCure, manages the fiscal health and capital allocation strategies necessary for medical device manufacturing. Overseeing financial reporting and investor relations, the Chief Financial Officer ensures transparency and accuracy in all economic disclosures. This leadership role involves optimizing resource distribution to support the research and development of innovative Afib treatment technologies. By analyzing market trends and operational costs, Angela Wirick strengthens the financial foundation required for sustained corporate growth. The Chief Financial Officer coordinates with other executive leaders to align budgetary priorities with the strategic goals of the company. Through disciplined fiscal oversight, Wirick mitigates financial risks while maximizing shareholder value. This executive function remains critical for maintaining the stability needed to scale production and expand the reach of medical solutions across diverse healthcare markets, ultimately supporting the long-term viability of the entire organization.

Douglas Seith, the Chief Operating Officer at AtriCure, directs the daily manufacturing processes and supply chain logistics for specialized cardiac surgical equipment. Overseeing internal scaling and production efficiency, the Chief Operating Officer ensures that high-quality medical devices reach clinical settings without delay. This leadership role involves streamlining operational workflows to meet the increasing demand for Atrial Fibrillation treatment technologies. By implementing advanced manufacturing protocols, Douglas Seith enhances the overall output capacity of the company. The Chief Operating Officer collaborates with cross-functional teams to maintain strict quality control standards across all production facilities. Through meticulous management of operational assets, Seith drives the execution of corporate objectives related to product availability and market penetration. This executive oversight guarantees that the infrastructure remains robust enough to support the rapid deployment of new medical innovations, ensuring that healthcare providers receive the necessary tools to treat patients effectively.

Karl Dahlquist, the Chief Legal Officer at AtriCure, governs the regulatory compliance and intellectual property strategies essential for a medical technology manufacturer. Overseeing legal frameworks and corporate governance, the Chief Legal Officer protects the proprietary innovations that define the company's market position. This leadership role involves navigating complex healthcare regulations to ensure that all products meet safety and efficacy standards. By managing contractual obligations and litigation risks, Karl Dahlquist provides the necessary legal security for ongoing research and development efforts. The Chief Legal Officer works closely with the executive team to align business practices with evolving global legal requirements. Through proactive risk assessment, Dahlquist safeguards the reputation and assets of the organization. This executive function remains vital for maintaining the integrity of the business model, allowing the company to focus on delivering advanced solutions for Atrial Fibrillation while operating within the strict boundaries of international medical law.